吉非替尼(Iressa)治疗晚期复治非小细胞肺癌的临床观察  

Clinical Experience of Treating Recurrent Terminal Non-small Cell Lung Cancer By Gefitinib(Iressa)

作　　者：谢晓冬[1] 郑振东[1] 刘大为[1] 张爽[2] 刘永叶[1] 张冠中[1] 单学健[1] 邢春景[1] 

机构地区：[1]沈阳军区总医院肿瘤科,沈阳市110016 [2]沈阳军区总医院医学训练队

出　　处：《中国肿瘤临床》2006年第10期574-576,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:总结吉非替尼(Iressa)治疗晚期复治非小细胞肺癌的临床经验及体会。方法:选取2003年12月至2005年2月经IressaEAP治疗的33例患者临床资料进行分析整理,评价其临床疗效、症状、生活质量、中位生存期、疾病进展时间及毒副反应。结果:病灶总缓解率为28.1%,总控制率为62.5%,临床症状改善率为63.6%,服药4周内KPS评分提高差异有显著性,患者中位生存期为3.3个月,疾病进展时间为3个月,未出现3～4级的毒性反应。结论:Iressa是一种有效且具有良好耐受性的分子靶向治疗药物,为晚期复发转移的非小细胞肺癌治疗提供了一条安全有效的途径。Objective： To sum up our clinical experience of treating terminal non-small cell lung cancer by gefitinib （Iressa）. Method： Clinical data of 33 patients were collected who received Iressa EAP therapy from Dec.2003 to Feb.2005. Evaluations were made about curative effects, symptoms, quality of life, mean survival time, time to progression and toxic reactions. Results： Total mitigative rate of the focus was 28.1%,total control rate was 62.5%, and alleviative rate of clinical symptoms was 63.6%. The difference of KPS grades was significant. Mean survival time of all the patients was 3.3 months. Time to progression was 3 months. - grades of toxic reaction were not found. Conclusion： Gefitinib is an effective molecule-target curative with good tolerance. It provides a safe and effective way for the treatment of recurrent terminal non-small cell lung cancer.

关 键 词：吉非替尼 非小细胞肺癌 分子靶向治疗 表皮生长因子受体 

分 类 号：R734.2[医药卫生—肿瘤]